North China Pharmaceutical (600812.SH) has forecasted a pre-increase, with an estimated net profit of around 125 million yuan in 2024, an increase of approximately 2456.08% year-on-year.

North China Pharmaceutical (600812.SH) announced that, according to preliminary calculations by the finance department, it is expected to achieve a net profit attributable to the owners of the parent company of approximately 125 million yuan in 2024, an increase of around 120.10 million yuan compared to the same period last year, representing a year-on-year increase of approximately 2456.08%. It is estimated that the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses will be around 107 million yuan in 2024, an increase of approximately 152.23 million yuan compared to the same period last year. During the reporting period, the company achieved profitability improvement through measures such as adjusting product structures, strengthening procurement management, reducing procurement costs, implementing lean management, and optimizing cost control.